Comprehensive medication guide to Ropinirole XR including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0–$30 copay on most plans; generic Ropinirole XR is Tier 1–2 on most Medicare Part D and commercial formularies. No prior authorization typically required.
Estimated Cash Pricing
$22–$87 retail per 30-day supply depending on strength (2 mg to 12 mg); as low as $15–$23 with GoodRx or SingleCare coupons.
Medfinder Findability Score
78/100
Summarize with AI
On this page
Ropinirole XR (extended-release) is a once-daily prescription tablet used to treat the symptoms of Parkinson's disease. It belongs to a class of medications called non-ergoline dopamine agonists — drugs that directly activate dopamine receptors in the brain, mimicking the neurotransmitter dopamine that is deficient in Parkinson's disease.
The brand-name version, Requip XL, was originally developed by GlaxoSmithKline and approved by the FDA in July 2008. In 2019, GSK discontinued Requip XL as a business decision due to declining demand following generic entry. Today, generic Ropinirole XR is produced by multiple manufacturers including Zydus Lifesciences, Alembic Pharmaceuticals, Accord Healthcare, and Dr. Reddy's Laboratories.
Ropinirole XR is available in five strengths: 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg extended-release tablets. It is FDA-approved only for Parkinson's disease (not Restless Legs Syndrome — for RLS, the immediate-release formulation is used). It is not a controlled substance.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
In Parkinson's disease, the dopamine-producing neurons in a brain region called the substantia nigra progressively degenerate. As dopamine levels fall, the brain's movement circuitry becomes dysregulated, causing the characteristic symptoms: tremors, rigidity, bradykinesia (slowness of movement), and balance problems.
Ropinirole does not restore dopamine itself — instead, it directly stimulates dopamine D2 and D3 receptors, bypassing the need for endogenous dopamine. It acts on G-protein-coupled inhibitory neurons, inhibiting adenylyl cyclase and calcium channels while activating potassium channels. This restores more normal motor circuit activity, reducing Parkinson's symptoms.
The extended-release formulation provides steady drug levels over 24 hours, helping to maximize "on" time (good motor control) and minimize "off" time (poor motor control) compared to the immediate-release version taken 2–3 times daily. Ropinirole is metabolized by the liver enzyme CYP1A2, and its levels are affected by drugs or substances that inhibit or induce this enzyme.
2 mg — Extended-release tablet
Starting dose for Parkinson's disease titration; taken once daily
4 mg — Extended-release tablet
Common maintenance dose; taken once daily
6 mg — Extended-release tablet
Intermediate maintenance dose; taken once daily
8 mg — Extended-release tablet
Higher maintenance dose; clinical studies show no added benefit above 8 mg/day in advanced PD
12 mg — Extended-release tablet
Higher maintenance dose; studies show no added benefit above 12 mg/day in early PD; maximum is 24 mg/day
As of 2026, generic Ropinirole XR does not have an active FDA-declared nationwide shortage. Multiple generic manufacturers produce the medication, and broad supply is adequate. However, localized availability gaps are common — particularly for the 2 mg extended-release tablet — due to pharmacy purchasing contracts, regional distribution variability, and the lingering effects of GlaxoSmithKline's 2019 discontinuation of brand-name Requip XL.
The 4 mg, 6 mg, 8 mg, and 12 mg strengths are generally more widely stocked than the 2 mg titration tablet. Patients in rural areas, or those who use chain pharmacies with limited distributor flexibility, are most likely to encounter availability challenges. Independent pharmacies and mail-order options often have better and more consistent supply.
If you are having trouble finding Ropinirole XR at your pharmacy, medfinder calls pharmacies near you to check which ones have it in stock and can fill your prescription. Results are texted to you — no hold music, no repeated calls.
Because Ropinirole XR is not a controlled substance, any licensed prescriber can prescribe it without special DEA registration. There are no restrictions on prescription quantity, refills, or prescribing method (including telehealth).
The following types of healthcare providers commonly prescribe Ropinirole XR:
Ropinirole XR is available via telehealth without restriction, as it is not a controlled substance. Telehealth neurology platforms and general telemedicine services can evaluate and prescribe for appropriate Parkinson's disease patients. This is especially valuable for patients with mobility limitations or those in rural areas with limited specialist access.
No. Ropinirole XR is not classified as a controlled substance by the Drug Enforcement Administration (DEA). It has no DEA schedule (not Schedule I through V).
This means there are no special restrictions on who can prescribe it, how prescriptions are written, how many refills are permitted, or how early a refill can be requested. Any licensed prescriber — including nurse practitioners and physician assistants — can write a prescription for Ropinirole XR. It can also be prescribed via telehealth without DEA registration for telemedicine controlled substances. Patients can fill their prescription early if needed, which is helpful when experiencing supply shortages.
The most commonly reported side effects include:
Know what you need? Skip the search.
Pramipexole (Mirapex / Mirapex ER)
Non-ergoline dopamine agonist in the same drug class; approved for both Parkinson's disease and RLS; generic widely available; approximate conversion is 1 mg pramipexole ≈ 5 mg ropinirole.
Rotigotine (Neupro)
Dopamine agonist delivered via once-daily transdermal patch; approved for Parkinson's disease and RLS; useful for patients with swallowing difficulties or GI intolerance; brand-only (no generic in U.S. as of 2026).
Carbidopa/Levodopa (Sinemet)
Gold standard for Parkinson's disease; most effective agent for motor symptoms; often used in combination with ropinirole in advanced disease; generic widely available.
Gabapentin Enacarbil (Horizant)
Non-dopaminergic option for Restless Legs Syndrome only (not Parkinson's disease); approved for moderate-to-severe RLS; no risk of impulse control disorders or augmentation.
Prefer Ropinirole XR? We can find it.
Fluvoxamine (Luvox)
majorPotent CYP1A2 inhibitor — significantly increases ropinirole blood levels. Use of an alternative antidepressant is generally recommended.
Ciprofloxacin (Cipro)
majorCYP1A2 inhibitor — increases ropinirole levels. Dose adjustment of ropinirole may be needed if ciprofloxacin is used concurrently.
Amisulpride
majorDopamine receptor antagonist — directly opposes ropinirole's mechanism. Combination is contraindicated.
Metoclopramide
majorDopamine receptor antagonist used for nausea — opposes ropinirole's therapeutic effects. Avoid combination.
Carbamazepine (Tegretol)
moderateCYP1A2 inducer — decreases ropinirole blood levels, potentially reducing efficacy. Monitor and adjust dose.
Cigarette smoking
moderateCYP1A2 inducer — smokers require higher ropinirole doses. Starting or stopping smoking requires dose adjustment.
Antipsychotics (haloperidol, risperidone, olanzapine)
moderateDopamine receptor antagonists — may reduce ropinirole efficacy. Note: FDA has warned of medication errors between risperidone and ropinirole due to name similarity.
CNS depressants / alcohol
moderateAdditive sedation — increases risk of excessive drowsiness and sudden sleep attacks. Avoid or use extreme caution.
Estrogen-containing medications
minorCYP1A2 inhibition — may increase ropinirole levels. Monitor for increased side effects.
Cimetidine (Tagamet)
minorCYP1A2 inhibitor — may increase ropinirole levels. Consider alternative acid suppression therapy.
Ropinirole XR is a well-established, FDA-approved treatment for Parkinson's disease with a strong evidence base built over more than 15 years of clinical use. As a once-daily extended-release generic, it offers convenience and affordability compared to many other neurological medications. The brand-name Requip XL may be gone, but generic ropinirole XR provides the same therapeutic benefit at substantially lower cost.
The key challenges for patients in 2026 are: (1) finding the medication in stock consistently at their pharmacy, particularly for lower strengths; and (2) never stopping the medication abruptly, which requires staying ahead of refill timing. Working with your neurologist, refilling early, and using tools to locate pharmacy stock are the most important strategies for uninterrupted access.
If you need help finding Ropinirole XR at a pharmacy near you, medfinder contacts local pharmacies on your behalf to find which ones have it in stock and can fill your prescription — saving you the frustration of calling pharmacy after pharmacy.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini